J
Jirousek Michael R
Researcher at Eli Lilly and Company
Publications - 14
Citations - 532
Jirousek Michael R is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Protein kinase C & Bryostatin 1. The author has an hindex of 5, co-authored 14 publications receiving 526 citations. Previous affiliations of Jirousek Michael R include University of Mississippi.
Papers
More filters
Journal ArticleDOI
Protein kinase C inhibitors as novel anticancer drugs
TL;DR: An antisense oligonucleotide, ISIS-3521 and two orally available small molecule inhibitors, LY 333531 and midostaurin, have now advanced to latter stage development for cancer and/or other indications and initial safety and early clinical efficacy have been encouraging.
Journal Article
Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development.
TL;DR: The role of PKC in some of the pathways relevant to cardiovascular, peripheral microvascular, CNS, oncology, immune and infectious disease states, and a survey of the current generation of potent and selective ATP-competitive inhibitors is provided.
Journal ArticleDOI
Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development
TL;DR: Protein kinase C (PKC) is a family of enzymes that play a ubiquitous role in intracellular signal transduction as discussed by the authors, and the development of potent and selective PKC inhibitors, including isozyme-selective inhibitors, has opened new avenues for biochemical and pharmaceutical studies.
Patent
Therapeutic treatment for VEGF related diseases
TL;DR: In this paper, a β-isozyme selective PKC inhibitor, (S)-3,4]-N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N, N-dimethylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione hydrochloride salt.
Patent
Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
TL;DR: In this article, a method for treating neoplasms was disclosed, particularly using the β-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N, N-dimethylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione or one of its salts, such PKC inhibitors enhance the clinical efficacy of oncolytic agents and radiation